Michael Jasulavic

Knight Capital Group, Inc. is a global financial services firm, which provides access to the capital markets across multiple asset classes to a broad network of clients, including buy and sell side firms, dealers, brokers, institutions, and corporations. It operates business through four segments: Market Making, Institutional Sales and Trading, Electronic Execution Services and Corporate and Other. The Market Making segment consists of market making in global equities and listed domestic options. It includes client, and to a lesser extent, non-client electronic market making activities in which they operate as a market maker in equity securities. The Institutional Sales and Trading segment includes global equity, exchange traded funds and fixed income sales and trading; reverse mortgage origination and securitization; capital markets; and asset management activities. Its business consists of execution and facilitation equities and fixed income transactions as agent on behalf of institutional clients, and they commit capital on behalf of its clients when needed. The Electronic Execution Services segment offers access via its electronic agency-based platforms to markets and self-directed trading in equities, equity options, fixed income, foreign exchange and futures contracts. The Corporate and Other segment invests in strategic financial services-oriented opportunities, allocates, deploys and monitors all capital, and maintains corporate overhead expenses and all other income and expenses that are not attributable to the other segments. The company was founded in 1995 and is headquartered in Jersey City, NJ.

HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.

Sivik Global Healthcare LLC, formerly Argus Management LLC, is a New York City-based hedge fund manager founded by former members of Galleon Management.

Founded by Barton Biggs in 2003, Traxis Partners LLC is a registered investment advisor located in Greenwich, Connecticut. The firm also manages a hedge fund portfolio for Morgan Stanley (NYSE: MWD).

CoreCommodity Management LLC (CoreCommodity) is a registered investment advisor and hedge fund manager headquartered in Stamford, Connecticut. The firm was founded by Adam de Chiara and Bradford Klein in 2003 as Jefferies Asset Management LLC and changed their name to CoreCommodity Management LLC in 2012. They are a subsidiary of CoreCommodity Capital LLC, which is owned by CoreManagement LLC. CoreCommodity provides investment management services to sovereign wealth funds, public and corporate pensions, endowments and foundations, and other prominent institutional clients seeking commodities exposure.

ConnectRN, Inc. operates as a mobile technology company connecting hospitals with available nurses. Its platform provides various tools to connect healthcare providers to qualified and available staff via an alert system that is sent to their mobile devices. The company is headquartered in Brookline, MA.

Tevard Biosciences, Inc. is a biotechnology company based in Cambridge, MA. Tevard Biosciences is focused on developing trna-based and other modulating therapies to cure a broad range of genetic diseases. The company is advancing the use of its novel suppressor trna, enhancer trna, and mrna amplifier platforms in neurological disorders, heart disease, and muscular dystrophies. The company was founded in 2017 by Warren Burt Lammert, Harvey F. Lodish, Daniel Fischer, and Jeffrey Coller. Daniel Fischer has been the CEO since 2017.

Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020.

SCRIPT Biosciences, Inc. develops a genome editing platform. The American company was founded in 2020. Anil Namboodiripad has been the CEO of the company since 2021.